ReviewGlycoconjugate journal2023
Strengths and weaknesses of pneumococcal conjugate vaccines.
Review in Glycoconjugate journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Effectiveness of pneumococcal vaccination in reducing hospitalization and mortality among the elderly: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2025Pooled it
- Serotype replacement and mobile genetic elements inMicrobial genomics · 2025Pooled it
- A Phase 2b Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 6-Valent Group B Streptococcus Vaccine Administered Concomitantly With Tetanus, Diphtheria, and Acellular Pertussis Vaccine in Healthy Nonpregnant Female Individuals.The Journal of infectious diseases · 2025Trial
- High-throughput antigen discovery using Functional Genomic Vaccinology (FGV) identifies protective Streptococcus pneumoniae vaccine candidates.Nature communications · 2026Article
- Yinhuapinggan granules regulate PI3K/AKT and RAS/MAPK pathways to inhibit Streptococcus Pneumoniae-induced inflammatory responses.Archives of microbiology · 2026Article
- The Burden of Streptococcus Pneumoniae-Related Admissions in Pediatric Population: A Retrospective Cohort Study Between Years 2018-2023 From a Southern Italian Region.Health science reports · 2026Article
- AI-Assisted Systematic Literature Review of the Economic Burden of Pneumococcal Disease: Development and Validation Study.JMIR AI · 2026Article
- Post-Vaccination Surveillance of Invasive Pneumococcal Disease in Ghana.Diseases (Basel, Switzerland) · 2026Article
- Persistence of vaccine-induced serotype-related pathology in invasive pneumococcal disease in children. Community of Madrid, 2007-2024.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- The Case for Pneumococcal Surface Protein A (PspA): A Comprehensive Review of a Leading Candidate in Pneumococcal Vaccine Research.Vaccines · 2026Review
- Future Pneumococcal Vaccines: Shifting from Capsular Polysaccharides to Protein-Based Immunogens.Vaccines · 2026Review
- Bioinformatic evaluation of ClpP as a vaccine target in Streptococcus pneumoniae.Biotechnology letters · 2026Article
- Synthetic Access to Fluorinated Analogs of a KnownACS organic & inorganic Au · 2026Article
- A protein-based pneumococcal vaccine elicits broad immunity associated with multifunctional antibody responses in humans.The Journal of clinical investigation · 2026Article
- Research progress on the current status of respiratory pathogen infections and their detection methods.Frontiers in microbiology · 2026Review
- Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses.NPJ vaccines · 2025Article
- Pneumococcal vaccination offer and schedules in adults in EU countries: An update.Human vaccines & immunotherapeutics · 2025Review
- Review
- Genomic Analysis of Glycosyltransferases Responsible for Galactose-α-1,3-Galactose Epitopes inVaccines · 2025Article
- Population Genetic Structure of Invasive and Non-InvasiveInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multivalent vaccines addressing an increasing number of Streptococcus pneumoniae types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years. The use of polysaccharide-protein conjugate vaccines has been pivotal in reducing the incidence of invasive pneumococcal disease despite the emergence of non-vaccine serotypes. Notwithstanding its undoubtable success, some weaknesses have called for continuous improvement of pneumococcal vaccination. For instance, despite their inclusion in pneumococcal conjugate vaccines, there are challenges associated with some serotypes. In particular, Streptococcus pneumoniae type 3 remains a major cause of invasive pneumococcal disease in several countries.Here a deep revision of the strengths and weaknesses of the licensed pneumococcal conjugate vaccines and other vaccine candidates currently in clinical development is reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.